[FG] Trendelenburg Marten

Kleer, Jessica S. et al. (2024) ‘Factor H-related protein 1 in systemic lupus erythematosus’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1447991.

Eckardt, Henrik et al. (2024) ‘Major low-energy trauma results in non-specific immunoglobulin generation without evidence for specific autoantibody production: A prospective cohort study’, Scandinavian Journal of Immunology, 99. Available at: https://doi.org/10.1111/sji.13368.

Isayeva, Ganna et al. (2024) ‘Diagnostic and prognostic value of mannan-binding lectin associated protein (MAp19) for functionally relevant coronary artery disease’, Clinica Chimica Acta, 558. Available at: https://doi.org/10.1016/j.cca.2024.119668.

Schulz, Kristina et al. (2023) ‘Complement C1q and von Willebrand factor interaction in atherosclerosis of human carotid artery’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1265387.

Breillat P et al. (2023) ‘Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study.’, Rheumatology (Oxford, England), 62(6), pp. 2189–2196. Available at: https://doi.org/10.1093/rheumatology/keac566.

Isayeva, Ganna et al. (2023) ‘Diagnostic and prognostic value of H-ficolin for functionally relevant coronary artery disease’, Clinica Chimica Acta, 551. Available at: https://doi.org/10.1016/j.cca.2023.117582.

Mihailovic, Jelena et al. (2023) ‘Worse cardiovascular and renal outcome in male SLE patients’, Scientific Reports, 13. Available at: https://doi.org/10.1038/s41598-023-45171-7.

Schulz, Kristina et al. (2023) ‘Complement C1q and von Willebrand factor interaction in atherosclerosis of human carotid artery’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1265387.

Urwyler, Pascal et al. (2023) ‘Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1255292.

Schulz K. and Trendelenburg M. (2022) ‘C1q as a target molecule to treat human disease: What do mouse studies teach us?’, Frontiers in Immunology, 13. Available at: https://doi.org/10.3389/fimmu.2022.958273.

Capoferri G et al. (2022) ‘Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis.’, Clinics in dermatology, 40(4), pp. 397–401. Available at: https://doi.org/10.1016/j.clindermatol.2022.02.013.

Costa A.E. et al. (2022) ‘Severe myopathy complicating multisystem inflammatory syndrome in adults (MIS-A) in a young man’, BMJ Case Reports, 15(7). Available at: https://doi.org/10.1136/bcr-2022-250054.

Gross S et al. (2022) ‘Perception of physicians and nursing staff members regarding outside versus bedside ward rounds: Ancillary analysis of the randomised BEDSIDE-OUTSIDE trial’, Swiss Medical Weekly, 152(3-4). Available at: https://doi.org/10.4414/smw.2022.w30112.

Kleer JS et al. (2022) ‘Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus’, Frontiers in Immunology, 12, p. 761395. Available at: https://doi.org/10.3389/fimmu.2021.761395.

Bruni F et al. (2022) ‘Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study.’, Frontiers in immunology, 13, p. 941742. Available at: https://doi.org/10.3389/fimmu.2022.941742.

Chasset F. et al. (2022) ‘Serum interferon-α levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity’, Annals of the Rheumatic Diseases, 81(6), pp. 901–903. Available at: https://doi.org/10.1136/annrheumdis-2021-221835.

Rabatscher P.A. and Trendelenburg M. (2022) ‘Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40–CD154-mediated inflammation in peripheral blood mononuclear cells in vitro’, Clinical and Translational Immunology, 11(8). Available at: https://doi.org/10.1002/cti2.1408.

Urwyler, Pascal et al. (2022) ‘Targeting thromboinflammation in COVID-19 – A narrative review of the potential of C1 inhibitor to prevent disease progression’, Molecular Immunology, 150, pp. 99–113. Available at: https://doi.org/10.1016/j.molimm.2022.08.008.

Vogt S et al. (2021) ‘Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial’, Respiratory Research, 22(1), p. 227. Available at: https://doi.org/10.1186/s12931-021-01822-9.

Charitos P. et al. (2021) ‘Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study’, Frontiers in Immunology, 12. Available at: https://doi.org/10.3389/fimmu.2021.765330.

Becker C et al. (2021) ‘Effect of bedside compared with outside the room patient case presentation on patients” knowledge about their medical care: A randomized, controlled, multicenter trial’, Annals of Internal Medicine, 174(9), pp. 1282–1292. Available at: https://doi.org/10.7326/m21-0909.

Kiener S. et al. (2021) ‘Variants affecting the C-terminal tail of UNC93B1 are not a common risk factor for systemic lupus erythematosus’, Genes, 12(8). Available at: https://doi.org/10.3390/genes12081268.

Mihailovic, J. et al. (2021) ‘Worse Cardiovascular and Renal Outcome in Male SLE Patients: First Gender Study From the Swiss SLE Cohort Study’. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-645732/v1.

Bertschi, Jasmin (2021) The impact of monocytes on CD3/D28 activated T cells upon anti-C1q autoantibody encounter. . Translated by Trendelenburg Marten; Ricklin Daniel. Masterarbeit.

Csorba K. et al. (2021) ‘Anti-C1q Autoantibodies: Standard Quantification and Innovative ELISA’. Humana Press Inc., pp. 107–114. Available at: https://doi.org/10.1007/978-1-0716-1016-9_10.

Trendelenburg M. (2021) ‘Autoantibodies against complement component C1q in systemic lupus erythematosus’, Clinical and Translational Immunology, 10(4). Available at: https://doi.org/10.1002/cti2.1279.

Urwyler, Pascal et al. (2021) ‘Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)’, Trials, 22(1). Available at: https://doi.org/10.1186/s13063-020-04976-x.

Kieninger-Gräfitsch A et al. (2020) ‘No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus’, Scientific Reports, 10(1), p. 3693. Available at: https://doi.org/10.1038/s41598-020-60523-3.

Chasset F et al. (2020) ‘Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.’, Rheumatology (Oxford, England), 59(11), pp. 3468–3478. Available at: https://doi.org/10.1093/rheumatology/keaa167.

Strasser DS et al. (2020) ‘Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus.’, RMD open, 6(2). Available at: https://doi.org/10.1136/rmdopen-2020-001261.

Panagiotou A et al. (2020) ‘A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury.’, JACC. Cardiovascular interventions, 13(7), pp. 833–842. Available at: https://doi.org/10.1016/j.jcin.2019.11.021.

Nigolian H et al. (2020) ‘Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus.’, Rheumatology (Oxford, England), 59(3), pp. 534–544. Available at: https://doi.org/10.1093/rheumatology/kez306.

Donat C et al. (2020) ‘Complement C1q Enhances Primary Hemostasis.’, Frontiers in immunology, 11, p. 1522. Available at: https://doi.org/10.3389/fimmu.2020.01522.

Sarcevic J et al. (2020) ‘Case Report-Secondary Antibody Deficiency Due to Endogenous Hypercortisolism.’, 11. Available at: https://doi.org/10.3389/fimmu.2020.01435.

Sarcevic, Jelena et al. (2020) ‘Secondary Antibody Deficiency Due to Endogenous Hypercortisolism’, Frontiers in Immunology, 11, p. 1435. Available at: https://doi.org/10.3389/fimmu.2020.01435.

Urwyler, Pascal et al. (2020) ‘Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System’, Frontiers in Immunology, 11. Available at: https://doi.org/10.3389/fimmu.2020.02072.

Vogt, Severin et al. (2020) ‘Local and Systemic Concentration of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases’, Frontiers in Immunology, 11, p. 562564. Available at: https://doi.org/10.3389/fimmu.2020.562564.

von Rotz, M. et al. (2019) ‘Aussergewöhnliche Ursache von Rückenschmerzen’, Swiss Medical Forum ‒ Schweizerisches Medizin-Forum [Preprint]. Available at: https://doi.org/10.4414/smf.2019.08340.

Friebus-Kardash J et al. (2019) ‘Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.’, BMC nephrology, 20(1), p. 430. Available at: https://doi.org/10.1186/s12882-019-1623-4.

Pröbstel AK et al. (2019) ‘Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus’, Rheumatology (United Kingdom), 58(5), pp. 908–913. Available at: https://doi.org/10.1093/rheumatology/key282.

Troldborg A et al. (2019) ‘Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus.’, Journal of clinical immunology, 39(4), pp. 421–429. Available at: https://doi.org/10.1007/s10875-019-00627-2.

Osthoff M et al. (2019) ‘Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: A cross-sectional study’, Arthritis Research and Therapy, 21(1). Available at: https://doi.org/10.1186/s13075-019-1859-1.

Csorba K et al. (2019) ‘Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site.’, Frontiers in immunology, 10, p. 2619. Available at: https://doi.org/10.3389/fimmu.2019.02619.

Donat C, Thanei S and Trendelenburg M (2019) ‘Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages.’, Frontiers in immunology, 10, p. 2712. Available at: https://doi.org/10.3389/fimmu.2019.02712.

Marchetti T et al. (2018) ‘Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus.’, Rheumatology (Oxford, England), 57(8), pp. 1350–1357. Available at: https://doi.org/10.1093/rheumatology/key095.

Troldborg A et al. (2018) ‘The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus.’, The Journal of rheumatology. 15.06.2018, 45(8), pp. 1136–1144. Available at: https://doi.org/10.3899/jrheum.171033.

Burkard T et al. (2018) ‘The heart in systemic lupus erythematosus - A comprehensive approach by cardiovascular magnetic resonance tomography.’, PloS one, 13(10), p. e0202105. Available at: https://doi.org/10.1371/journal.pone.0202105.

Dahdal S et al. (2018) ‘Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus.’, PloS one. 24.01.2018, 13(1), p. e0188695. Available at: https://doi.org/10.1371/journal.pone.0188695.

Friebus-Kardash J et al. (2018) ‘Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus.’, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 33(1), pp. 54–64. Available at: https://doi.org/10.1093/ndt/gfx220.

Nehring J et al. (2018) ‘Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus.’, Frontiers in immunology. 02.10.2018, 9, p. 2090. Available at: https://doi.org/10.3389/fimmu.2018.02090.

Panagiotou A, Trendelenburg M and Osthoff M (2018) ‘The Lectin Pathway of Complement in Myocardial Ischemia/Reperfusion Injury-Review of Its Significance and the Potential Impact of Therapeutic Interference by C1 Esterase Inhibitor.’, Frontiers in immunology, 9, p. 1151. Available at: https://doi.org/10.3389/fimmu.2018.01151.

Trendelenburg, Marten et al. (2018) ‘Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival’, European heart journal. Acute cardiovascular care, 7(4), pp. 348–357. Available at: https://doi.org/10.1177/2048872617694674.

Thanei S et al. (2017) ‘Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages.’, Biochemical pharmacology. 04.10.2017, 146, pp. 151–164. Available at: https://doi.org/10.1016/j.bcp.2017.10.001.

Osthoff M et al. (2017) ‘Association of Lectin Pathway Protein Levels and Genetic Variants Early after Injury with Outcomes after Severe Traumatic Brain Injury: A Prospective Cohort Study.’, Journal of neurotrauma, 34(17), pp. 2560–2566. Available at: https://doi.org/10.1089/neu.2016.4941.

Huber, Xaver et al. (2017) ‘Primary intestinal lymphangiectasia in an elderly female patient: A case report on a rare cause of secondary immunodeficiency.’, Medicine, 96(31), p. e7729. Available at: https://doi.org/10.1097/md.0000000000007729.

Kofler T et al. (2017) ‘[Abdominal pain and hypertension in a 55-year-old male patient].’, Der Internist, 58(4), pp. 397–401. Available at: https://doi.org/10.1007/s00108-016-0170-3.

Chaigne B et al. (2017) ‘Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).’, BMC immunology. 28.03.2017, 18(1), p. 17. Available at: https://doi.org/10.1186/s12865-017-0200-5.

Thanei S and Trendelenburg M (2017) ‘Anti-C1q autoantibodies from patients with systemic lupus erythematosus induce C1q production by macrophages.’, Journal of leukocyte biology. 14.09.2016, 101(2), pp. 481–491. Available at: https://doi.org/10.1189/jlb.3a1215-535r.

Kolm, R. et al. (2016) ‘Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling’, J Immunol, 197(9), pp. 3669–3679. Available at: https://doi.org/10.4049/jimmunol.1501876.

Osthoff, Michael et al. (2016) ‘Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland’, The Journal of infection, 72(3), pp. 377–85. Available at: https://doi.org/10.1016/j.jinf.2015.12.011.

Thanei, S. and Trendelenburg, M. (2016) ‘Anti-C1q Autoantibodies from Systemic Lupus Erythematosus Patients Induce a Proinflammatory Phenotype in Macrophages’, J Immunol, 196(5), pp. 2063–74. Available at: https://doi.org/10.4049/jimmunol.1501659.

Vitkova, H. et al. (2016) ‘Anti-C1q autoantibodies are linked to autoimmune thyroid disorders in pregnant women’, Clin Exp Immunol, 186(1), pp. 10–7. Available at: https://doi.org/10.1111/cei.12813.

Stegert M, Bock M and Trendelenburg M (2015) ‘Clinical presentation of human C1q deficiency: How much of a lupus?’, Molecular immunology, 67(1), pp. 3–11. Available at: https://doi.org/10.1016/j.molimm.2015.03.007.

Bock, Merete, Heijnen, Ingmar and Trendelenburg, Marten (2015) ‘Anti-C1q antibodies as a follow-up marker in SLE patients’, PLoS ONE, 10(4), p. e0123572. Available at: https://doi.org/10.1371/journal.pone.0123572.

Koenig, K. F. et al. (2015) ‘Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts’, Lupus, 24(1), pp. 58–65. Available at: https://doi.org/10.1177/0961203314550223.

Mandal, Jyotshna et al. (2015) ‘Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study’, Respir Res, 16, p. 150. Available at: https://doi.org/10.1186/s12931-015-0306-3.

Pesickova, Satu Sinikka et al. (2015) ‘Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up’, Arthritis Research & Therapy, 17, p. 371. Available at: https://doi.org/10.1186/s13075-015-0879-8.

Thanei, Sophia, Vanhecke, Dominique and Trendelenburg, Marten (2015) ‘Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways’, Clinical Immunology, 160(2), pp. 180–7. Available at: https://doi.org/10.1016/j.clim.2015.06.014.

Schifferli J.A. and Trendelenburg M. (2014) ‘Cryoglobulinemia and chronic HCV infection: An evolving story’. Springer-Verlag Italia s.r.l., pp. 79–83. Available at: https://doi.org/10.1007/978-88-470-1705-4_9.

Nytrova, Petra et al. (2014) ‘Complement activation in patients with neuromyelitis optica’, Journal of Neuroimmunology, 274(1-2), pp. 185–91. Available at: https://doi.org/10.1016/j.jneuroim.2014.07.001.

Ribi C et al. (2014) ‘The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.’, Swiss medical weekly. 07.08.2014, 144, p. w13990. Available at: https://doi.org/10.4414/smw.2014.13990.

Scharein P and Trendelenburg M (2013) ‘Critical incidents in a tertiary care clinic for internal medicine.’, BMC research notes. 16.07.2013, 6, p. 276. Available at: https://doi.org/10.1186/1756-0500-6-276.

Trendelenburg, M. and Ribi, C. (2013) ‘Systemischer Lupus Erythematodes – die «Swiss SLE Cohort Study (SSCS)»’, Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 13(22). Available at: https://doi.org/10.4414/smf.2013.01532.

Egli, A. et al. (2013) ‘Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients’, PLoS ONE, 8(1), p. e51983. Available at: https://doi.org/10.1371/journal.pone.0051983.

Osthoff M and Trendelenburg M (2013) ‘Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction.’, BioMed research international, 2013(1), p. 962695. Available at: https://doi.org/10.1155/2013/962695.

Potlukova E et al. (2013) ‘Association between low levels of Mannan-binding lectin and markers of autoimmune thyroid disease in pregnancy.’, PloS one, 8(12), p. e81755. Available at: https://doi.org/10.1371/journal.pone.0081755.

Vanhecke D. et al. (2012) ‘Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay’, Arthritis and Rheumatism, 64(11), pp. 3706–3714. Available at: https://doi.org/10.1002/art.34605.

Osthoff M et al. (2012) ‘Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial.’, BMC nephrology. 03.09.2012, 13, p. 99. Available at: https://doi.org/10.1186/1471-2369-13-99.

Trendelenburg M. (2012) ‘The complement system in cryoglobulinemia’. Springer-Verlag Italia s.r.l., pp. 85–89. Available at: https://doi.org/10.1007/978-88-470-1705-4_10.

Hirt-Minkowski, P. et al. (2012) ‘A trial of complement inhibition in a patient with cryoglobulin-induced glomerulonephritis’, Case Reports in Nephrology and Urology, 2(1), pp. 38–45. Available at: https://doi.org/10.1159/000339403.

Koenig, Katrin Franzika et al. (2012) ‘Serum cytokine profile in patients with active lupus nephritis’, Cytokine, 60(2), pp. 410–6. Available at: https://doi.org/10.1016/j.cyto.2012.07.004.

Koenig, K. F. et al. (2012) ‘MBL serum levels in patients with sepsis correlate with thyroid function but not with outcome’, Clinical Immunology, 144(1), pp. 80–2. Available at: https://doi.org/10.1016/j.clim.2012.05.002.

Trendelenburg M (2012) ‘Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis: comment on the article by Katsumata et al.’, 64(1). Available at: https://doi.org/10.1002/art.33384.

Osthoff M et al. (2011) ‘Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients’, PLoS ONE, 6(6). Available at: https://doi.org/10.1371/journal.pone.0021338.

Benz, Nadja et al. (2011) ‘Three cases of primary small vessel vasculitis of the skeletal muscle-an own entity’, BMJ case reports, 2011, p. Nov 8. Available at: https://doi.org/10.1136/bcr.08.2011.4631.

Bigler, Cornelia et al. (2011) ‘Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis’, Nephrology, dialysis, transplantation, 26(4), pp. 1220–8. Available at: https://doi.org/10.1093/ndt/gfq558.

Osthoff, Michael et al. (2011) ‘Mannose-binding lectin - the forgotten molecule?’, Nature medicine, 17(12), p. 1547–8; author reply 1548. Available at: https://doi.org/10.1038/nm.2588.

Osthoff, M. et al. (2011) ‘Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients’, PLoS ONE, 6(6), p. e21338. Available at: https://doi.org/10.3410/f.717949101.793454250.

Knecht, Margrith E et al. (2010) ‘A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13.’, Nephrology, dialysis, transplantation, 25(5), pp. 1720–2. Available at: https://doi.org/10.1093/ndt/gfq021.

Osthoff, Michael et al. (2010) ‘Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantation’, Haematologica, 95(8), pp. 1389–96. Available at: https://doi.org/10.3324/haematol.2009.017863.

Potlukova, Eliska et al. (2010) ‘The production of mannan-binding lectin is dependent upon thyroid hormones regardless of the genotype : a cohort study of 95 patients with autoimmune thyroid disorders’, Clinical immunology, 136(1), pp. 123–9. Available at: https://doi.org/10.1016/j.clim.2010.02.015.

Trendelenburg, Marten et al. (2010) ‘Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention’, European heart journal, 31(10), pp. 1181–7. Available at: https://doi.org/10.1093/eurheartj/ehp597.

Vetter, M., Battegay, M. and Trendelenburg, M. (2010) ‘Primary cytomegalovirus infection with accompanying Pneumocystis jiroveci pneumonia in a patient with large-vessel vasculitis’, Infection, 38(4), pp. 331–4. Available at: https://doi.org/10.1007/s15010-010-0024-1.

Chizzolini C et al. (2009) ‘[Towards the Swiss systemic lupus erythematosus cohort study (SSCS)].’, Revue medicale suisse, 5(199), pp. 808–11.

Bigler, Cornelia et al. (2009) ‘Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells’, Journal of immunology : official journal of the American Association of Immunologists, 183(5), pp. 3512–21. Available at: https://doi.org/10.4049/jimmunol.0803573.

Chizzolini, Carlo et al. (2009) ‘Création d’unecohorte suisse de patients lupiques : the Swiss systemic lupus erythematosus cohort study (SSCS)’, Revue médicale suisse : revue officielle de la Société médicale de la Suisse romande ... [et al.], 5(199), pp. 808–11.

Schaller, Monica et al. (2009) ‘Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven’, Journal of immunology : official journal of the American Association of Immunologists, 183(12), pp. 8225–31. Available at: https://doi.org/10.4049/jimmunol.0902642.

Arici B. and Trendelenburg M. (2008) ‘Successful treatment of thrombotic thrombocytopenic purpura (TTP) with Rituximab Erfolgreiche behandlung einer thrombotisch thrombozytopenischen purpura mit rituximab’, Therapeutische Umschau, 65(12), pp. 710–712. Available at: https://doi.org/10.1024/0040-930.65.12.710.

Trendelenburg M. (2008) ‘From smolder to blaze - Pathogenesis and mechanisms of inflammation Vom glimmen zur glut - Pathogenese und mechanismen entzündlicher prozesse’, Aktuelle Ernahrungsmedizin, 33(SUPPL. 1). Available at: https://doi.org/10.1055/s-2007-986416.

Ottl T and Trendelenburg M (2008) ‘[Cryoglobulinemia].’, Therapeutische Umschau. Revue therapeutique, 65(5), pp. 253–8. Available at: https://doi.org/10.1024/0040-5930.65.5.253.